Trial Profile
A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary) ; Daratumumab/hyaluronidase (Primary) ; Bortezomib; Carfilzomib; Dexamethasone; Dexamethasone; Lenalidomide; Melphalan; Prednisone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Acronyms PLEIADES
- Sponsors Janssen Research & Development; Janssen-Cilag
- 30 Jan 2024 Planned End Date changed from 30 Nov 2023 to 29 Feb 2024.
- 08 Nov 2023 Planned End Date changed from 29 Sep 2023 to 30 Nov 2023.
- 16 Aug 2023 Planned End Date changed from 31 Jul 2023 to 29 Sep 2023.